Haemonetics vs Neogen
Haemonetics (HAE) and Neogen (NEOG) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $5.47B
- Last close
- $120.16
- 12 months
- +60.0%
- Market value
- $2.3B
- Last close
- $10.55
- 12 months
- +95.0%
At a glance
- The biggest part of Haemonetics's revenue is Hospital (44%); at Neogen it is Food Safety (74%).
- Haemonetics earns 74% of its revenue in the United States, Neogen 49%.
- By market value, Haemonetics ($5.5B) is about 2.4 times Neogen ($2.3B).
- Over the last 12 months Haemonetics's share price moved +60.0% and Neogen's +95.0%; against the S&P 500 that is +54.2 points and +89.3 points.
- In their last fiscal years Haemonetics kept 7.3% of revenue as net income and Neogen -0.9%.
- In the last 90 days insiders reported 0 open-market purchases at Haemonetics and 0 at Neogen; members of Congress disclosed 0 trades in Haemonetics and 0 in Neogen.
- Next results: Haemonetics Feb 3, 2027, Neogen Jan 6, 2027.
How each one makes money: Haemonetics revenue · Neogen revenue
Share prices on one chart
Haemonetics and Neogen, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Haemonetics HAENYSE · Health Care Supplies | Neogen NEOGNASDAQ · Health Care Supplies | |
|---|---|---|
| Size and profitability | ||
| Market value | $5.47B | $2.3B |
| Revenue, last fiscal year | $1.33B | $870M |
| Net income, last fiscal year | $97.3M | −$7.9M |
| Net marginNet income as a share of revenue | 7.3% | -0.9% |
| Free cash flow | $260M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Haemonetics different from Neogen?
Haemonetics (HAE) is in Health Care Supplies on NYSE, with $1.33B of revenue in its last fiscal year and a net margin of 7.3%. Neogen (NEOG) is in Health Care Supplies on NASDAQ, with $870M of revenue in its last fiscal year and a net margin of -0.9%. The biggest part of Haemonetics's revenue is Hospital (44%); at Neogen it is Food Safety (74%). Haemonetics earns 74% of its revenue in the United States, Neogen 49%. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Haemonetics and Neogen compare in size?
Haemonetics has the larger market value: Haemonetics $5.47B and Neogen $2.3B, at the last close.
Whose share price rose more over the last 12 months, HAE or NEOG?
Over the last 12 months Haemonetics moved +60.0% and Neogen +95.0%. Past price moves say nothing about the future.
Which has had more insider buying, Haemonetics or Neogen?
Since 2006, Haemonetics insiders reported 142 open-market purchases against 96 for Neogen. These are counts of what was filed, not a view on either stock.
Do members of Congress trade HAE or NEOG?
In the last 12 months, members of Congress disclosed 0 trades in Haemonetics (HAE) and 0 in Neogen (NEOG).
When did insiders last buy HAE and NEOG?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Haemonetics pageNeogen pageRare insider trades this weekAll comparisons
https://oqro.io/compare/hae-vs-neog

